ProMIS Neurosciences secured up to $175 million in PIPE financing to support its ongoing Phase 1b clinical trial of PMN310, a potential Alzheimer's treatment targeting toxic amyloid-beta oligomers. The PRECISE-AD trial is fully enrolled with 144 participants, with a blinded 6-month interim safety and biomarker analysis expected in early Q3 2026 and full 12-month top-line results anticipated in early 2027. This financing ensures funding through 2027, enabling completion of the trial and further development, including a subcutaneous formulation to improve patient convenience. The company aims to offer a safer alternative to current Alzheimer's therapies by avoiding plaque binding and reducing risks like ARIA, a serious side effect associated with existing treatments.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
